Core Insights - uniQure is a clinical-stage biotechnology company focused on developing gene therapies, gaining attention from analysts due to promising drug development milestones [1][2] - Recent analyst upgrades reflect optimism about uniQure's potential, with price targets set at $31, $35, and $60 by Chardan Capital, RBC Capital, and Wells Fargo respectively [2][6] - The departure of Vinay Prasad from the FDA is viewed positively, potentially leading to a more favorable regulatory environment for uniQure's Huntington's disease treatment [3][6] Stock Performance - Currently, QURE is priced at $17.99, showing a significant increase of 26.07% with a change of $3.72 [4] - The stock has fluctuated between a low of $16.03 and a high of $18.20 today, with a market capitalization of approximately $1.11 billion [4] - Over the past year, QURE reached a high of $71.50 and a low of $7.76, indicating substantial volatility [4] Investor Interest - The trading volume for QURE today is 15,334,548 shares, indicating strong investor interest [5] - Analysts believe there is substantial upside potential as the company approaches key drug development milestones, suggesting the market has not fully accounted for uniQure's chances of success [5]

Core Viewpoint - FuelCell Energy, Inc. reported mixed financial results for Q1 2026, showing a significant year-over-year revenue growth but falling short of revenue expectations, leading to a decline in stock price. Financial Performance - The company reported an earnings per share (EPS) of -$0.49, which was better than the estimated EPS of -$0.68 [2][6] - Revenue for the quarter was $30.5 million, missing the forecast of $43.3 million and $42.2 million [2][3] - Despite the revenue miss, the company achieved a 61% increase in revenue year over year [3][6] Strategic Initiatives - CEO Jason Few highlighted improvements in operating discipline and liquidity, with a 20% reduction in operating loss [4] - The GAAP loss of $0.49 per share marked a significant improvement from the previous year's Q1 loss of $1.42 per share [4] Market Sentiment - Wall Street analysts remain skeptical about the company's path to profitability, not expecting it to occur before 2030 [4][6] Valuation Metrics - The price-to-sales ratio is approximately 2.08, and the enterprise value to sales ratio is about 0.32, indicating a relatively low valuation compared to sales [5] - The debt-to-equity ratio stands at 0.044, reflecting a low level of debt relative to equity [5] - The current ratio is approximately 7.96, indicating a strong ability to cover short-term liabilities [5]

Core Viewpoint - Cisco Systems Inc. is a leading technology company with a strong market presence, and analysts maintain a positive outlook on its future performance, reflected in its stock ratings and market capitalization [1][5]. Group 1: Analyst Ratings - Bank of America Securities has reiterated its "Buy" rating for Cisco, indicating confidence in the company's future performance [1][5]. - The average brokerage recommendation (ABR) for Cisco is 1.79, suggesting a favorable outlook, with 15 out of 26 brokerage firms giving a Strong Buy recommendation [2][5]. - Over 61% of all recommendations for Cisco are Strong Buy or Buy, highlighting the positive sentiment from analysts [3]. Group 2: Stock Performance - Cisco's current stock price is $76.21, reflecting a decrease of 3.09% or $2.43 from the previous trading session [3][5]. - The stock has traded between a low of $75.20 and a high of $77.56 on the current day, with a yearly high of $88.19 and a low of $52.11 [3]. - The trading volume for the day is 31,373,993 shares, indicating active investor interest [4]. Group 3: Market Capitalization - Cisco's market capitalization is approximately $301.1 billion, underscoring its significant role in the technology industry [4][5].

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Banco Santander, S.A. (NYSE: SAN) resulting from allegations that Santander may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Santander securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr ...

Voyager Technologies, Inc. (VOYG) reported $46.65 million in revenue for the quarter ended December 2025, representing no change year over year. EPS of -$0.37 for the same period compares to $0 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $48.03 million, representing a surprise of -2.88%. The company delivered an EPS surprise of -11.28%, with the consensus EPS estimate being -$0.33.While investors scrutinize revenue and earnings changes year-over-year and how they compare with ...

VANCOUVER, BC / ACCESS Newswire / March 9, 2026 / FutureGen Industries Corp. (formerly Right Season Investments Corp.) (TSXV:LITT)(Frankfurt:T500, WKN:A41WY4) ("FutureGen Industries" or the "Company") announces that it has entered into a debt settlement agreement with a director of the Company (the "Creditor") dated March 9, 2026 (the "Settlement Agreement") pursuant to which the Company has agreed to issue the Creditor 100,800 common shares of the Company (each, a "Share" and, collectively, the "Shares") a ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Banco Santander, S.A. ("Banco Santander†or the "Company†) (NYSE: SAN) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BANCO SANTANDER, S.A. (SAN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On February 27, 2026, the Financial Times reported that l. ...

Core Viewpoint - Olema Pharmaceuticals Inc. is focused on developing targeted therapies for women's cancers, particularly breast cancer, with its leading project being Palazestrant, a new class of treatments [1][4] Company Overview - Olema Pharmaceuticals Inc. is a biopharmaceutical company dedicated to women's cancer therapies, with strategic collaborations with pharmaceutical giants like Pfizer Inc. and Novartis AG [1][4] - The company's leading project, Palazestrant, is a complete estrogen receptor antagonist and selective estrogen receptor degrader [1] Stock Performance - On March 9, 2026, H.C. Wainwright set a price target of $38 for Olema, indicating a potential upside of approximately 69% from a trading price of $16.45 [2] - The stock has recently declined to $16.30, marking a decrease of 24.36% from its previous price, attributed to disappointing results from Roche Holdings AG's phase 3 study [2] - Olema's stock has shown significant volatility, with a trading range over the past year between $2.86 and $36.26, and a market capitalization of approximately $1.28 billion [3][4]

VersionsEnglish$Cashtags$SCHWHashtags#APIs#AccountOpening#ClientOnboarding#Fintech#RIA#WealthManagement#WealthTech#WorkflowAutomation- --### ContactsFeatheryZack Khan zack@feathery.ioPeter Dun peter@feathery.ioSocial Media ProfilesFeathery on LinkedIn account opening via API, enabling firms to open Schwab accounts directly from onboarding workflows.Release VersionsEnglish$Cashtags$SCHWHashtags#APIs#AccountOpening#ClientOnboarding#Fintech#RIA#WealthManagement#WealthTech#WorkflowAutomation- --### ContactsFeat ...

Core Viewpoint - Telix Pharmaceuticals Limited has successfully achieved the primary objectives of Part 1 of the ProstACT Global Phase 3 study for its therapeutic candidate TLX591-Tx, demonstrating an acceptable safety and tolerability profile with no new safety signals observed [1][5]. Study Findings - Part 1 confirmed the safety profile, biodistribution, and dosimetry of TLX591-Tx administered in two doses, 14 days apart, in combination with standard of care therapies: abiraterone, enzalutamide, or docetaxel [2][5]. - The patient population consisted of prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with one androgen receptor pathway inhibitor (ARPI) [2][5]. Trial Design - ProstACT Global is a differentiated Phase 3 trial comparing PSMA-targeted 177Lu-rADC therapy administered with standard of care versus standard of care alone, reflecting current global clinical practice [3]. - The study has advanced into Part 2, a 2:1 randomized treatment expansion, in regions where clinical trial approval has been obtained [3]. Expert Commentary - Neeraj Agarwal, MD, noted that the results support the feasibility of integrating TLX591-Tx with current standard therapies for mCRPC, with hematologic events aligning with expectations and resolving quickly [4]. - David N. Cade, MD, emphasized the need for improved treatment options for advanced prostate cancer and highlighted the potential of TLX591-Tx to become a new first-line option [4]. Summary Results - A total of 36 patients were dosed in Part 1, with an acceptable safety profile observed across combination cohorts [5][6]. - The tolerability profile was supported by dosimetry and low-grade non-hematologic events, with no adverse drug-drug interactions observed [6][15]. Dosimetry and Biodistribution - Lesion dosimetry indicated no difference in absorbed dose profile across cohorts, and radiation exposure to key organs was well below established safety limits [6][15]. - Pharmacokinetics demonstrated sustained activity at 15 days, corroborated by imaging showing prolonged tumor retention [15]. Additional Information - ProstACT Global is an international, multicenter trial with an overall target enrollment of approximately 490 patients, focusing on confirmed progressive mCRPC assessed with a 68Ga-PSMA-11 PET imaging agent [9][24]. - TLX591-Tx has not yet received marketing authorization in any jurisdiction [12].